<DOC>
	<DOCNO>NCT00333840</DOCNO>
	<brief_summary>The purpose study evaluate compare side effect anti-leukemic benefit imatinib interferon Ara-C patient chronic myeloid leukemia ( CML ) chronic phase . Patients study randomize ( 1:1 ) receive either interferon plus Ara-C imatinib initial treatment .</brief_summary>
	<brief_title>Safety Efficacy Imatinib Versus Interferon-Î± Plus Cytarabine Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : Must sign consent Amendment 5 Must complete visit 62 core IRIS trial followup Must STI571 treatment If IFN treatment , must willing cross STI571 treatment Exclusion criterion : Patients discontinue study followup Patients IFN treatment want cross STI571 treatment Patients consent amendment 5 Patients complete amendment 5 protocol Additional protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>CML</keyword>
	<keyword>STI571</keyword>
	<keyword>imatinib</keyword>
	<keyword>interferon</keyword>
	<keyword>interferon alpha</keyword>
	<keyword>cytosine arabinoside</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>Philadelphia chromosome positive</keyword>
</DOC>